Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may cut bleeding risk for heart patients on strong meds

NCT ID NCT04654052

Disease control Sponsor: Fundación EPIC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a blood test can help doctors safely lower the dose of strong blood thinners (P2Y12 inhibitors) in people who recently had a heart attack or stent. The goal is to reduce bleeding complications without raising the risk of another heart attack or stroke. About 634 adults who are already on dual antiplatelet therapy will be monitored for up to one year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 634 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with age 18 years or above. * Patient is able to understand the nature of study and has provided written informed consent. * Patients with Acute Coronary Syndrome and who underwent PCI during the admission, who have been discharged on double. antiplatelet therapy with Acetylsalicylic Acid and Ticagrelor or Prasugrel. Exclusion Criteria: * Patients with history of intracranial bleeding. * Patients with contraindication for the use of Acetylsalicylic Acid or Clopidogrel or Ticagrelor or Prasugrel. * Patients with major ischemic or hemorrhagic events during the first month. * Patients with Thrombocytopenia \<50,000 /µL. * Patients with permanent oral anticoagulation. * Patient is pregnant or breast feeding. * Patients with impossibility to complete 1 year of follow-up. * Patient´s life-expectancy is less than 24 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome acute myocardial infarction coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndrome Acute myocardial infarction Coronary artery disease Percutaneous coronary intervention

Contacts and locations

Locations

  • Hospital Clinico Universitario de Valladolid

    Valladolid, 47003, Spain

  • Hospital Del Mar

    Barcelona, 08003, Spain

  • Hospital General Universitario de Albacete

    Albacete, 02006, Spain

  • Hospital General Universitario de Ciudad Real

    Ciudad Real, 13005, Spain

  • Hospital San Pedro de Alcantara

    Cáceres, 10003, Spain

  • Hospital Universitari Vall D Hebron

    Barcelona, 08035, Spain

  • Hospital Universitari de Bellvitge

    L'Hospitalet de Llobregat, 08907, Spain

  • Hospital Universitario Juan Ramon Jimenez

    Huelva, 21005, Spain

  • Hospital Universitario Lozano Blesa

    Zaragoza, 50009, Spain

  • Hospital Universitario Lucus Agusti

    Lugo, 27003, Spain

  • Hospital Universitario Marques de Valdecilla

    Santander, 39008, Spain

  • Hospital Universitario Miguel Servet

    Zaragoza, 50009, Spain

  • Hospital Universitario Regional de Malaga

    Málaga, 29010, Spain

  • Hospital Universitario Virgen de La Arrixaca

    El Palmar, Murcia, 30120, Spain

  • Hospital Universitario Virgen de Las Nieves

    Granada, 18014, Spain

  • Hospital Universitario de Cabueñes

    Gijón, 33394, Spain

  • Hospital Universitario de Galdakao-Usansolo

    Galdakao, 48960, Spain

  • Hospital Universitario de Salamanca

    Salamanca, 37007, Spain

  • Hospital de León

    León, 24080, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.